logo
episode-header-image
Sep 2025
36m 11s

Episode 139: Follicular Lymphoma Series,...

Rouleaux University Medical Center
About this episode
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to revie ... Show More
Up next
Aug 19
Episode 161: Career Development Series- Building a Career in Clinical Research
This week, we are so excited to share the third episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidan ... Show More
27m 42s
Aug 12
Episode 160: Head and Neck Cancer Series, Pt. 3 – Discussion with ENT
Throughout this series, we have discussed how multidisciplinary the management of head and neck cancer is and the critical role that our surgical colleagues play in the management of this disease. This week, we welcome Dr. Michael Topf, Associate Professor for Associate Professor ... Show More
36 m
Aug 5
Episode 159: Head and Neck Cancer Series, Pt. 2 – Locoregional Disease
This week we get into treatment. Building on Part 1's (episode 158: https://www.thefellowoncall.com/tfocpodcast/hncintro) workup and staging, we walk through three cases to highlight the important distinguishing details: an oral cavity cancer, a locally advanced oropharynx cancer ... Show More
34m 43s
Recommended Episodes
Dec 2023
Follicular Lymphoma
<p>This week’s episode will be focusing on one of the Non-Hodgkin Lymphomas: Follicular Lymphoma. We will go over the important details on diagnostic criteria, indications for treatment and treatment options.</p> 
12 m
Dec 2024
Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation
In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who rec ... Show More
20m 5s
Aug 2025
Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson
In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific anti ... Show More
43m 3s
May 2023
Multiple Myeloma
<p>This week’s episode is part 2 of our plasma cell dyscrasias series. We will go over the important details on risk stratification, as well as initial and relapse treatment options for Multiple Myeloma, with key details on the pharmacology of myeloma drugs.</p><p><br/></p> 
16m 47s
Sep 2025
S2 Episode 3: When Is the Best Time to Use CAR T-Cell Therapy in Multiple Myeloma?
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ... Show More
24m 38s
Nov 2025
Bispecific Antibodies in Aggressive B-Cell Lymphoma: Real-World Insights and Future Directions
In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-ce ... Show More
9m 36s
Mar 2025
Chemotherapy: Biologics
In this episode, we’ll be discussing biologic and other targeted therapies in gyn oncology, including indications and management of toxicities. Join us for bi-weekly episodes or check out our episode archive and show notes at readysetgyo.com. Follow us on Instagram @ReadySetGYOPo ... Show More
26m 47s
Aug 2024
EHA 2024 Recap: Optimizing the Relapsed/Refractory CLL Treatment Pathway
<p>How can you optimize the treatment pathway for relapsed or refractory chronic lymphocytic leukemia (CLL)? Join the experts as they delve into the latest updates from EHA 2024.<br />   <br /> Credit available for this activity expires: 07/31/25<br /> Earn Credit / Learning Obje ... Show More
37m 22s
Oct 2024
Outdated: Cervix Part 2: Locally Advanced Cervical Cancer
This is the second of three episodes covering cervical cancer. In this episode, we define locally advanced, metastatic, and recurrent cervical cancer. We will discuss the standard treatment options, including chemotherapy and immunotherapy choices. Join us for bi-weekly episodes ... Show More
39m 43s
Apr 2024
CAR T-Cells and Safety Signals
This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701. 
25m 25s